Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Accumulated Expenses (2018 - 2025)

Immucell's Accumulated Expenses history spans 14 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 13.65% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, down 13.65%, while the annual FY2025 figure was $1.0 million, 13.65% down from the prior year.
  • Accumulated Expenses reached $1.0 million in Q4 2025 per ICCC's latest filing, up from $977466.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.5 million in Q1 2022 to a low of $291111.0 in Q1 2021.
  • Average Accumulated Expenses over 5 years is $909308.7, with a median of $953382.0 recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 420.81% in 2022, then plummeted 50.54% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $585939.0 in 2021, then skyrocketed by 64.96% to $966553.0 in 2022, then fell by 2.44% to $942999.0 in 2023, then grew by 26.8% to $1.2 million in 2024, then decreased by 13.65% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Accumulated Expenses are $1.0 million (Q4 2025), $977466.0 (Q3 2025), and $1.1 million (Q2 2025).